secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0000105770-23-000043
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q2 net sales $753.8M (-2.3%), adjusted EPS $2.11; raises FY2023 guidance
--------------------------------------------------------------------------------

- Reported Q2 diluted EPS of $2.06; adjusted diluted EPS of $2.11, down from $2.47 YoY.
- Net sales declined 2.3% to $753.8M; organic net sales fell 2.5%.
- Proprietary Products segment sales down 5.5% to $618.0M, driven by COVID-19 related decline; base business grew double digits.
- Contract-Manufactured Products segment sales up 15.3% to $135.8M, led by injection-device components.
- FY2023 net sales guidance raised to $2.970-2.995B; adjusted EPS guidance raised to $7.65-7.80.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577023000043/0000105770-23-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577023000043/wst-20230727.htm
  HTML page:      https://secwatch.observer/filing/0000105770-23-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer